It is currently unclear whether plasma biomarkers can be used as independent prognostic
tools to predict changes associated with early Alzheimer's disease. In this study, we sought …

Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of
Alzheimer's disease (AD) because they are more available and cost-effective than …

Introduction Plasma markers have been reported to be associated with brain amyloid
burden, tau pathology, or neurodegeneration. We aimed to evaluate whether plasma …

Recently, low-sensitive plasma assays have been replaced by new ultra-sensitive assays
such as single molecule enzyme-linked immunosorbent assay (Simoa), the Mesoscale …

Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …

Objective The objective of this study was to evaluate novel plasma p‐tau231 and p‐tau181,
as well as Aβ40 and Aβ42 assays as indicators of tau and Aβ pathologies measured with …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

Background To facilitate population screening and clinical trials of disease-modifying
therapies for Alzheimer's disease, supportive biomarker information is necessary. This study …